Cargando…

Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease

Cognitive deficits in Parkinson’s disease typically affect executive functions. Recently, the concept of Mild Cognitive Impairment (MCI) has been related to PD (PD-MCI). PD-MCI is considered a transition phase to Parkinson’s disease Dementia. Therefore, it is important to identify PD-MCI in a reliab...

Descripción completa

Detalles Bibliográficos
Autores principales: Broche-Pérez, Yunier, Bartuste-Marrer, Danay, Batule-Domínguez, Miriam, Toledano-Toledano, Filiberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação de Neurologia Cognitiva e do Comportamento 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907705/
https://www.ncbi.nlm.nih.gov/pubmed/31844492
http://dx.doi.org/10.1590/1980-57642018dn13-040005
_version_ 1783478580887420928
author Broche-Pérez, Yunier
Bartuste-Marrer, Danay
Batule-Domínguez, Miriam
Toledano-Toledano, Filiberto
author_facet Broche-Pérez, Yunier
Bartuste-Marrer, Danay
Batule-Domínguez, Miriam
Toledano-Toledano, Filiberto
author_sort Broche-Pérez, Yunier
collection PubMed
description Cognitive deficits in Parkinson’s disease typically affect executive functions. Recently, the concept of Mild Cognitive Impairment (MCI) has been related to PD (PD-MCI). PD-MCI is considered a transition phase to Parkinson’s disease Dementia. Therefore, it is important to identify PD-MCI in a reliable way. Objective: To evaluate the sensitivity and specificity of the INECO Frontal Screening (IFS) in detecting cognitive deficits in PD-MCI. Additionally, we compare the IFS and the Addenbrook Cognitive Examination Revised (ACE-R) between three groups; PD-MCI, MCI, and controls. Methods: The IFS and ACE-R were administered to 36 patients with PD-MCI, 31 with MCI (amnestic-multidomain subtype) and 92 healthy controls. Sensitivity and specificity were determined using ROC analysis. The groups were compared using one-way analysis of variance. Results: The IFS had adequate accuracy in differentiating patients with PD-MCI from healthy controls (AUC=0.77, sensitivity=0.82, specificity=0.77), and good accuracy in differentiating PD-MCI from MCI patients (AUC=0.80, sensitivity=0.82, specificity=0.61). However the IFS had low accuracy in differentiating MCI patients from healthy controls (AUC=0.47, sensitivity=0.52, specificity=0.41). On the ACE-R, the PD-MCI group had low performance in Fluency and Language. Only patients with PD-MCI had difficulties on the IFS, specifically in inhibitory control and visual working memory. This dysexecutive profile explains the sensitivity and specificity values found in the IFS. Conclusion: The present study results suggest that the IFS is a suitable screening tool for exploring cognitive dysfunction in PD-MCI, especially in those patients with a dysexecutive profile.
format Online
Article
Text
id pubmed-6907705
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Associação de Neurologia Cognitiva e do Comportamento
record_format MEDLINE/PubMed
spelling pubmed-69077052019-12-16 Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease Broche-Pérez, Yunier Bartuste-Marrer, Danay Batule-Domínguez, Miriam Toledano-Toledano, Filiberto Dement Neuropsychol Original Article Cognitive deficits in Parkinson’s disease typically affect executive functions. Recently, the concept of Mild Cognitive Impairment (MCI) has been related to PD (PD-MCI). PD-MCI is considered a transition phase to Parkinson’s disease Dementia. Therefore, it is important to identify PD-MCI in a reliable way. Objective: To evaluate the sensitivity and specificity of the INECO Frontal Screening (IFS) in detecting cognitive deficits in PD-MCI. Additionally, we compare the IFS and the Addenbrook Cognitive Examination Revised (ACE-R) between three groups; PD-MCI, MCI, and controls. Methods: The IFS and ACE-R were administered to 36 patients with PD-MCI, 31 with MCI (amnestic-multidomain subtype) and 92 healthy controls. Sensitivity and specificity were determined using ROC analysis. The groups were compared using one-way analysis of variance. Results: The IFS had adequate accuracy in differentiating patients with PD-MCI from healthy controls (AUC=0.77, sensitivity=0.82, specificity=0.77), and good accuracy in differentiating PD-MCI from MCI patients (AUC=0.80, sensitivity=0.82, specificity=0.61). However the IFS had low accuracy in differentiating MCI patients from healthy controls (AUC=0.47, sensitivity=0.52, specificity=0.41). On the ACE-R, the PD-MCI group had low performance in Fluency and Language. Only patients with PD-MCI had difficulties on the IFS, specifically in inhibitory control and visual working memory. This dysexecutive profile explains the sensitivity and specificity values found in the IFS. Conclusion: The present study results suggest that the IFS is a suitable screening tool for exploring cognitive dysfunction in PD-MCI, especially in those patients with a dysexecutive profile. Associação de Neurologia Cognitiva e do Comportamento 2019 /pmc/articles/PMC6907705/ /pubmed/31844492 http://dx.doi.org/10.1590/1980-57642018dn13-040005 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Broche-Pérez, Yunier
Bartuste-Marrer, Danay
Batule-Domínguez, Miriam
Toledano-Toledano, Filiberto
Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease
title Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease
title_full Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease
title_fullStr Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease
title_full_unstemmed Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease
title_short Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease
title_sort clinical utility of the ineco frontal screening for detecting mild cognitive impairment in parkinson’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907705/
https://www.ncbi.nlm.nih.gov/pubmed/31844492
http://dx.doi.org/10.1590/1980-57642018dn13-040005
work_keys_str_mv AT brocheperezyunier clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease
AT bartustemarrerdanay clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease
AT batuledominguezmiriam clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease
AT toledanotoledanofiliberto clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease